For a patient with limited/resectable metastatic melanoma and no evidence of disease after resection, when would you consider doublet immunotherapy rather than nivolumab or pembrolizumab monotherapy?

This is an interesting question. I would say the standard approach would be to use anti PD1 alone. There was an interesting trial presented at ESMO 2019, the IMMUNED trial, that was a phase 2 randomized trial comparing the use of combination ipilimumab and nivolumab compared to nivolumab alone for r...